Rapid Micro Biosystems, Inc. today announced that it will be participating in the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021.
LOWELL, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems (Nasdaq: RPID) (“Rapid Micro” or the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it will be participating in the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021.
Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a virtual 30-minute question-and-answer session at 6:20am Pacific Time/9:20am Eastern Time. A live webcast of the session will be available on the Company’s website at https://investors.rapidmicrobio.com/. The webcast will then be archived and available for replay for 90 days following the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company’s flagship Growth Direct® System automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct® System brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products. The company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn.
Investor Contact: David Deuchler Gilmartin Group LLC investors@rapidmicrobio.com Media Contact: media@rapidmicrobio.com
